

Client Information (required)

| | | |
|--------------------|------------------|----------|
| Client Name | | |
| Client Account No. | | |
| Client Phone | Client Order No. | |
| Address | | |
| City | State | Zip Code |

Submitting Provider/Provider Name Information (required)

| |
|---|
| Submitting/Referring Provider <i>(Last, First)</i> |
| Fill in only if Call Back is required. Phone () _____ - _____ Fax * () _____ - _____ |
| Provider's National I.D. (NPI) |

**Fax number given must be from a fax machine that complies with applicable HIPAA regulation.*

"I hereby confirm that informed consent has been signed by an individual legally authorized to do so and is on file with this office or the individual's provider's office."

Signature _____

Note: It is the client's responsibility to maintain documentation of the order.

Patient Information (required)

| | | |
|---|---|----------|
| Patient ID <i>(Medical Record No.)</i> | | |
| Patient Name <i>(Last, First, Middle)</i> | | |
| Gender <input type="checkbox"/> Male <input type="checkbox"/> Female | Birth Date <i>(Month DD, YYYY)</i> | |
| Collection Date <i>(Month DD, YYYY)</i> | Time <input type="checkbox"/> a.m. <input type="checkbox"/> p.m. | |
| Patient's Street Address | | |
| Phone | | |
| City | State | Zip Code |

Reason for Referral (required)

| |
|-----------------------|
| |
| ICD-10 Diagnosis Code |

Note: It is the client's responsibility to maintain documentation of the order.
New York State Patients: Informed Consent for Genetic Testing

| |
|------------------------------|
| MCL Internal Use Only |
|------------------------------|

Ship specimens to:

Mayo Clinic Laboratories
3050 Superior Drive NW
Rochester, MN 55901

Customer Service: 855-516-8404

Visit www.MayoClinicLabs.com for the most up-to-date test and shipping information.

Billing Information

- An itemized invoice will be sent each month.
- Payment terms are net 30 days.

Call the Business Office with billing related questions:
800-447-6424 (US and Canada)
507-266-5490 (outside the US)

Patient Information (required)

| | |
|---|--------------------|
| Patient ID <i>(Medical Record No.)</i> | Client Account No. |
| Patient Name <i>(Last, First, Middle)</i> | Client Order No. |
| Birth Date <i>(Month DD, YYYY)</i> | |

| ALZHEIMER'S DISEASE | |
|--------------------------------|--|
| <input type="checkbox"/> ADEVL | Alzheimer's Disease Evaluation, Spinal Fluid |
| <input type="checkbox"/> APOEG | Apolipoprotein E Genotyping, Blood |

| AUTOIMMUNE CNS AND PARANEOPlastic DISORDERS | |
|---|---|
| <input type="checkbox"/> ENS2 | Encephalopathy, Autoimmune Evaluation, Serum (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, VGCC-N, VGCC-P/Q, AChR Ganglionic, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF) |
| <input type="checkbox"/> ENC2 | Encephalopathy, Autoimmune Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF) |
| <input type="checkbox"/> PAVAL | Paraneoplastic, Autoantibody Evaluation, Serum (VGKC, VGCC-P/Q, VGCC-N, AChR Binding, AChR Ganglionic, PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, Striational) |
| <input type="checkbox"/> PAC1 | Paraneoplastic, Autoantibody Evaluation, Spinal Fluid (PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin) |
| <input type="checkbox"/> GD65S | Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Serum |
| <input type="checkbox"/> GD65C | Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Spinal Fluid |

| Pediatric CNS Disorders | |
|--------------------------------|---|
| <input type="checkbox"/> PCDEC | Pediatric Autoimmune Central Nervous System Disorders Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, GABA, AQP4, DPPX, mGluR1, PCA-Tr, ANNA-1, GAD65, GFAP) |
| <input type="checkbox"/> PCDES | Pediatric Autoimmune Central Nervous System Disorders Evaluation, Serum (NMDA, LGI1, CASPR2, GABA, AQP4, MOG, DPPX, mGluR1, VGCC-N, VGCC-P/Q, AChR Ganglionic, PCA-Tr, ANNA-1, GAD65, GFAP) |

| DEMENTIA | |
|-------------------------------|--|
| Autoimmune Dementia | |
| <input type="checkbox"/> DMS2 | Dementia, Autoimmune Evaluation, Serum (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, VGCC-N, VGCC-P/Q, AChR Ganglionic, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF) |
| <input type="checkbox"/> DMC2 | Dementia, Autoimmune Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF) |

| Creutzfeldt Jakob Disease | |
|--------------------------------|--|
| <input type="checkbox"/> NSESF | Neuron-Specific Enolase (NSE), Spinal Fluid |
| Frontotemporal Dementia | |
| <input type="checkbox"/> C9ORF | C9orf72 Hexanucleotide Repeat, Molecular Analysis |
| <input type="checkbox"/> MAPTZ | MAPT Gene, Sequence Analysis, 7 Exon Screening Panel |
| <input type="checkbox"/> GRNZ | Progranulin Gene (GRN), Full Gene Analysis |

| DEMYELINATING DISEASE | |
|--------------------------------|--|
| <input type="checkbox"/> CDS1 | CNS Demyelinating Disease Evaluation, Serum (AQP4, MOG) |
| <input type="checkbox"/> NMOFS | Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum |
| <input type="checkbox"/> MOGFS | Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum |
| <input type="checkbox"/> KCSF | Immunoglobulin Kappa Free Light Chain, Spinal Fluid |
| <input type="checkbox"/> MSP3 | Multiple Sclerosis (MS) Profile, Serum and Spinal Fluid |

| DEVELOPMENTAL DELAY | |
|---------------------------------|--|
| <input type="checkbox"/> CMACB | Chromosomal Microarray, Congenital, Blood |
| <input type="checkbox"/> FXS | Fragile X Syndrome, Molecular Analysis |
| <input type="checkbox"/> PWAS | Prader-Willi/Angelman Syndrome, Molecular Analysis |
| <input type="checkbox"/> MEC2PZ | MECP2 Gene, Full Gene Analysis |

| DYSAUTONOMIA | |
|-------------------------------|---|
| <input type="checkbox"/> DYS2 | Autoimmune Dysautonomia Evaluation, Serum (DPPX, VGKC, VGCC-P/Q, VGCC-N, AChR Binding, AChR Ganglionic, ANNA-1, GAD65, Striational) |

| EPILEPSY | |
|-------------------------------|---|
| Autoimmune Epilepsy | |
| <input type="checkbox"/> EPS2 | Epilepsy, Autoimmune Evaluation, Serum (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, VGCC-N, VGCC-P/Q, AChR Ganglionic, PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP) |
| <input type="checkbox"/> EPC2 | Epilepsy, Autoimmune Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP) |

| Hereditary Epilepsy | |
|--|---|
| <input type="checkbox"/> ESPAN | Epilepsy/Seizure Genetic Panels by Next-Generation Sequencing (NGS) |
| Select one subpanel from the list below. | |
| <input type="checkbox"/> | Custom Gene Panel Custom ID _____ |
| <input type="checkbox"/> | Early Epileptic Encephalopathy Panel (90 genes) |
| <input type="checkbox"/> | Encephalopathy with Seizures Panel (129 genes) |
| <input type="checkbox"/> | Epilepsy with Migraine Panel (7 genes) |
| <input type="checkbox"/> | Epilepsy Expanded Panel (192 genes) |
| <input type="checkbox"/> | Febrile Seizure Panel (9 genes) |
| <input type="checkbox"/> | Focal Epilepsy Panel (16 genes) |
| <input type="checkbox"/> | Infantile Spasms Panel (17 genes) |
| <input type="checkbox"/> | Neuronal Migration Disorders Panel (29 genes) |
| <input type="checkbox"/> | Progressive Myoclonic Epilepsy Panel (27 genes) |
| <input type="checkbox"/> | Tuberous Sclerosis Panel (2 Genes) |

| FOLLOW-UP TESTING - NEUROIMMUNOLOGY | |
|-------------------------------------|--|
| <input type="checkbox"/> PNEFS | Neuroimmunology Antibody Follow-up, Serum Specify Antibody _____ |
| <input type="checkbox"/> PNEFC | Neuroimmunology Antibody Follow-up, Spinal Fluid Specify Antibody _____ |

| MENINGITIS | |
|--------------------------------|---|
| <input type="checkbox"/> CSFME | Meningitis/Encephalitis Pathogen Panel, PCR, Spinal Fluid |

Patient Information (required)

| | |
|---|--------------------|
| Patient ID <i>(Medical Record No.)</i> | Client Account No. |
| Patient Name <i>(Last, First, Middle)</i> | Client Order No. |
| Birth Date <i>(Month DD, YYYY)</i> | |

MITOCHONDRIAL DISORDERS

- GDF15 Growth Differentiation Factor 15, Plasma
- MITOP Mitochondrial Full Genome Analysis by Next-Generation Sequencing (NGS)
- MITON Mitochondrial Nuclear Gene Panel by Next-Generation Sequencing (NGS)
- MITOT Combined Mitochondrial Analysis, Mitochondrial Full Genome and Nuclear Gene Panel

MOVEMENT DISORDERS

Autoimmune Movement Disorders

- GD65S Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Serum
- GD65C Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Spinal Fluid
- GLYCS Glycine Receptor Alpha1 IgG, Cell Binding Assay, Serum
- GLYCC Glycine Receptor Alpha1 IgG, Cell Binding Assay, Spinal Fluid
- MDS2 Movement Disorder, Autoimmune Evaluation, Serum (NMDA, LGI1, CASPR2, DPPX, MGluR1, VGCC-N, VGCC-P/Q, AChR Ganglionic, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GRAF1, ITPR1, NIF)
- MDC2 Movement Disorder, Autoimmune Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, DPPX, MGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GRAF1, ITPR1, NIF)

Hereditary Movement Disorders

- DRPL Dentatorubral-Pallidolusian Atrophy (DRPLA) Gene Analysis
- FFRWB Friedreich Ataxia, Frataxin, Quantitative, Whole Blood
- HAD Huntington Disease, Molecular Analysis

MYASTHENIA GRAVIS

- MGRM Myasthenia Gravis (MG) Evaluation with MuSK Reflex, Serum (AChR Modulating, AChR Binding, Striational)
- MGA1 Myasthenia Gravis (MG) Evaluation, Adult, Serum (AChR Modulating, AChR Binding, Striational)
- MGP1 Myasthenia Gravis (MG) Evaluation, Pediatric, Serum (AChR Modulating, AChR Binding)
- MGT1 Myasthenia Gravis (MG) Evaluation, Thymoma, Serum (AChR Modulating, Ganglionic AChR, VGKC, AChR Binding, Striational, CRMP-5, GAD65)
- MGL1 Myasthenia Gravis (MG)/Lambert-Eaton Syndrome (LES) Evaluation, Serum (VGCC-P/Q, VGCC-N, AChR Modulating, AChR Binding, Striational)

Stand-Alone Antibodies

- ARBI Acetylcholine Receptor (Muscle AChR) Binding Antibody, Serum
- MUSK Muscle-Specific Kinase (MuSK) Autoantibody, Serum

MYELOPATHY

- MAS1 Autoimmune Myelopathy Evaluation, Serum (AQP4, MOG, DPPX, mGluR1, VGCC-N, VGCC-P/Q, PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF)
- MAC1 Autoimmune Myelopathy Evaluation, Spinal Fluid (AQP4, DPPX, mGluR1, PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF)

NEUROMUSCULAR

Autoimmune Neuromuscular

Myopathy

- NMS1 Necrotizing Myopathy Evaluation, Serum (HMGR, SRP)

Multifocal Motor Neuropathy

- GM1B Ganglioside Antibody Panel, Serum (Monosialo GM1, IgG; Monosialo GM1, IgM; Asialo GM1, IgG; Asialo GM1, IgM; GD1b, IgG; GD1b, IgM)

Sensory and Motor Neuropathy

- PAVAL Paraneoplastic, Autoantibody Evaluation, Serum (VGKC, VGCC-P/Q, VGCC-N, AChR Binding, AChR Ganglionic, PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, Striational)
- CRMWS Collapsin Response-Mediator Protein-5-IgG, Western Blot, Serum
- GD65S Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Serum

Hereditary Neuromuscular

Neuromuscular Disorders

- NMPAN Neuromuscular Genetic Panels by Next-Generation Sequencing (NGS)

Select one subpanel from the list below.

- Custom Gene Panel
Custom ID _____
- Distal Myopathy + Peripheral Neuropathy
 - Distal Weakness Expanded Panel (217 genes)

Myopathies

- Myopathy Expanded Panel (141 genes)
- Muscular Dystrophy Panel (77 genes)
- Congenital Myopathy Panel (36 genes)
- Metabolic Myopathy Panel (41 genes)
- Myofibrillar Myopathy Panel (12 genes)
- Distal Myopathy Panel (27 genes)
- Emery-Dreifuss Panel (5 genes)
- Rhabdomyolysis and Myopathy Panel (31 genes)

Motor Neuron Disease

- Motor Neuron Disease Panel (17 genes)

Neuromuscular Junction

- Congenital Myasthenic Syndromes Panel (25 genes)

Hyperexcitable Muscle Disease

- Skeletal Muscle Channelopathy Panel (6 genes)

- DBMD Duchenne/Becker Muscular Dystrophy, DMD Gene, Large Deletion/Duplication Analysis
- SMNDX Spinal Muscular Atrophy Diagnostic Assay, Deletion/Duplication Analysis
- SBULB Spinal Muscular Atrophy (Kennedy Disease), Molecular Analysis

NEUROPATHY

Autoimmune Neuropathy

- AIAES Autoimmune Axonal Evaluation, Serum (LGI1, CASPR2, AChR Ganglionic, ANNA-1, ANNA-3, AGNA-1, PCA-1)

Hereditary Peripheral Neuropathy

- NPPAN Peripheral Neuropathy Genetic Panels by Next-Generation Sequencing (NGS), Blood

Select one subpanel from the list below.

- Custom Gene Panel
Custom ID _____
- Hereditary Motor Neuropathy Panel (23 genes)
- Hereditary Sensory Neuropathy Panel (18 genes)
- Metabolic or Syndromic Neuropathies (74 genes)
- Motor and Sensory Neuropathy Panel (82 genes)
- Peripheral Neuropathy Expanded Panel (193 genes)
- SEPT9 Gene, Full Gene Analysis (1 gene)
- Spastic Paraplegia Neuropathy Panel (41 genes)

SLEEP DISORDERS

- ORXNA Orexin-A/Hypocretin-1, Spinal Fluid

Patient Information (required)

| | |
|---|--------------------|
| Patient ID <i>(Medical Record No.)</i> | Client Account No. |
| Patient Name <i>(Last, First, Middle)</i> | Client Order No. |
| Birth Date <i>(Month DD, YYYY)</i> | |

| THERAPEUTIC TESTING / DRUG MONITORING | |
|---------------------------------------|--|
| Antiepileptic Drugs | |
| <input type="checkbox"/> | AMOBS Amobarbital, Serum |
| <input type="checkbox"/> | CARTA Carbamazepine, Total, Serum |
| <input type="checkbox"/> | CDP Chlordiazepoxide and Metabolite, Serum |
| <input type="checkbox"/> | DIA Diazepam and Nordiazepam, Serum |
| <input type="checkbox"/> | ETX Ethosuximide, Serum |
| <input type="checkbox"/> | FELBA Felbamate (Felbatol), Serum |
| <input type="checkbox"/> | GABA Gabapentin, Serum |
| <input type="checkbox"/> | LACO Lacosamide, Serum |
| <input type="checkbox"/> | LAMO Lamotrigine, Serum |
| <input type="checkbox"/> | LEVE Levetiracetam, Serum |
| <input type="checkbox"/> | OMHC Oxcarbazepine Metabolite (MHC), Serum |
| <input type="checkbox"/> | PBR Phenobarbital, Serum |
| <input type="checkbox"/> | PNYA Phenytoin, Total, Serum |
| <input type="checkbox"/> | PRMB Primidone and Phenobarbital, Serum |
| <input type="checkbox"/> | SECOS Secobarbital, Serum |
| <input type="checkbox"/> | TOPI Topiramate, Serum |
| <input type="checkbox"/> | VALPA Valproic Acid, Total, Serum |
| <input type="checkbox"/> | ZONI Zonisamide, Serum |

| | |
|--------------------------|---|
| Pharmacogenomics | |
| <input type="checkbox"/> | PGXFP Focused Pharmacogenomics Panel (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, SLC01B1, VKORC1, CYP4F2, and rs12777823) |
| <input type="checkbox"/> | CARPB Carbamazepine Hypersensitivity Pharmacogenomics, Blood |
| <input type="checkbox"/> | COMTV Catechol-O-Methyltransferase (COMT) Genotype |
| <input type="checkbox"/> | 1A2V Cytochrome P450 1A2 Genotype |
| <input type="checkbox"/> | 2C19V Cytochrome P450 2C19 Genotype |
| <input type="checkbox"/> | 2C9GV Cytochrome P450 2C9 Genotype |
| <input type="checkbox"/> | 2D6CV Cytochrome P450 2D6 (CYP2D6) Comprehensive Cascade |
| <input type="checkbox"/> | 3A4V Cytochrome P450 3A4 Genotype |
| <input type="checkbox"/> | 3A5V CYP3A5 Genotype |
| <input type="checkbox"/> | TPNUV Thiopurine Methyltransferase (TPMT) and Nudix Hydrolase (NUDT15) Genotyping |
| <input type="checkbox"/> | WARSV Warfarin Response Genotype |

| ADDITIONAL TESTS (INDICATE TEST NUMBER AND NAME) |
|---|
| |